BESIVANCE has proven safety1
BESIVANCE has an established safety profile in clinical trials.

The most common non-ocular adverse event was headache (1-2%). Please see Important Safety Information below.
Pediatric Safety
BESIVANCE can be used to treat bacterial conjunctivitis in children as young as 12 months.2
BESIVANCE has an established safety profile in pediatric patients.3

Please see Important Safety Information below.